Table 3.
Studies that explore quality of life and anxiety in inflammatory bowel disease patients in remission with irritable bowel syndrome-like symptoms
| Ref. | Sample size (CD/UC) | Questionnaires used | Results |
| Simrén et al[2] | 83 (40/43) | GSRS | Higher anxiety and depression scores in IBD-IBS (worst in CD) |
| 37 IBD-IBS (23/14) | HADS | ||
| STAI | |||
| PGWB | |||
| Minderhoud et al[44] | 107 (34/73) | IBDQ | Lower QoL scores in IBD-IBS |
| 37 IBD-IBS (14/23) | |||
| Farrokhyar et al[45] | 149 (105/44) | sIBDQ | Occurence of any FGID taken in count (not only IBS-like) |
| 31 IBD-IBS (27/4) | EQ-5D | Lower QoL scores in CD patients with FGID | |
| Difference not significant for UC | |||
| Ansari et al[46] | 50 (0/50) | SF-36 | Lower QoL scores in IBD-IBS than in asymptomatic and similar to patients in flare |
| IBD-IBS: 23 (0/23) | |||
| Keohane et al[33] | 106 (62/44) | IBSQ | QoL scores only significantly lower in UC-IBS |
| 54 IBD-IBS (37/17) | HADS | Levels of anxiety and depression only significantly higher in UC-IBS | |
| Piche et al[48] | 92 (92/0) | French-validated IBS severity scoring system | Higher severity, impact, depression and fatigue scores in CD-IBS |
| 42 IBD-IBS (42/0) | |||
| Likert scales | No significant differences in anxiety level | ||
| FIS | |||
| Short BDI | |||
| HADS | |||
| Barratt et al[3] | 276 (110/166) | SF-36 | No differentiation between IBD patients in remission or in active phase |
| 31 IBD-IBS (14/17) | HADS | Lower QoL scores and higher anxiety, depression scores in IBD-IBS | |
| Bryant et al[4] | 93 (47/43) | sIBDQ | Occurrence of any FGID taken in count (not only IBS-like) |
| 12 IBD-IBS (no CD/UC differentiation) | HADS | Lower QoL scores and higher anxiety and depression scores in IBD patients with any FGID | |
| BDQ-6 | |||
| Lowest scores in IBS-like symptoms | |||
| Jelsness-Jørgensen et al[49] | 89(28/61) | FQ | More fatigue scores in IBD-IBS (worst in UC) |
| 30 IBD-IBS (8/22) | RFIPC | More concerns in UC-IBD (difference non significant for CD) | |
| Kim et al[50] | 226 (107/119) | EQ-5D | Occurrence of any FGID taken in count (not only IBS-like) |
| 82 IBD-IBS (50/32) | HADS | Lower QoL scores and higher anxiety and depression scores in UC-IBS (difference non-significant for CD) | |
| Berrill et al[5] | 97 (40/57) | HADS | No differentiation between IBD patients in remission or in active phase |
| 31 IBD-IBS (13/18) | Higher anxiety and depression scores in IBD-IBS | ||
| Jonefjäll et al[35] | 94 (0/94) | HADS | Lower QoL scores and higher anxiety scores in UC-IBS (difference in depression score non-significant) |
| 25 IBD-IBS (0/25) | SF-36 | ||
| Vivinus-Nébot et al[51] | 49 (31/18) | French-validated IBS severity scoring system | Higher severity and impact scores in IBD-IBS |
| 18 IBD-IBS (11/7) |
IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; GSRS: Gastrointestinal symptom rating scale; HADS: Hospital anxiety and depression scale; STAI: Spielberger state trait anxiety inventory; PGWB: Psychological general well-being index; IBSQ: Inflammatory bowel disease questionnaire; QoL: Quality of life; sIBDQ: Inflammatory bowel disease questionnaire; EQ-5D: EuroQOL-5D; FGID: Functional gastrointestinal disorders; FIS: Fatigue impact scale; BDI: Becks depression inventory; BDQ-6: Bowel disease questionnaire-6; FQ: Fatigue questionnaire; RFIPC: Rating form of inflammatory bowel disease patients concerns.